J&J Medical Connect
SYMTUZA®

(darunavir/ cobicistat/ emtricitabine/ tenofovir alafenamide)

J&J Medical Connect

Connect with us

  • Products

This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.

SYMTUZA® (darunavir/ cobicistat/ emtricitabine/ tenofovir alafenamide)
Medical Information

Use of SYMTUZA for Post-Exposure Prophylaxis

Last Updated: 07/22/2026

SUMMARY

  • SYMTUZA® is not indicated for use in post-exposure prophylaxis (PEP) for the prevention of HIV infection.1
  • There are no published data evaluating the use of SYMTUZA for PEP.

Literature Search

A literature search of MEDLINE®, EMBASE®, BIOSIS Previews®, and DERWENT® databases (and/or other resources, including internal/external databases) conducted on 03 September 2025. No relevant literature pertaining to this topic was identified.

References

Show
1 Data on File. Darunavir/Cobicistat/Emtricitabine/Tenofovir alafenamide. Company Core Data Sheet. Janssen Research & Development, LLC. EDMS-ERI-119231875; 2021.  

Would you like to clear and leave your conversation? Message history will be lost.